Eyestem: Eyestem to start human trials for its Dry AMD treatment

Eyestem, a cell therapy company, has received approval from India's Central Drugs Standards Control Organisation (CDSCO) to commence human trials for Eyecyte RPE , aimed at combating geographic atrophy arising from dry age-related macular degeneration (AMD). Dr. Jogin Desai, Founder and Chief Executive Officer, Eyestem, said, "The commencement of human trials represents a significant and proud [...]The post Eyestem to start human trials for its Dry AMD treatment appeared first on MediaBrief.